预约演示
更新于：2025-12-07
Ilaprazole
艾普拉唑
更新于：2025-12-07
概要
基本信息
药物类型 小分子化药 |
别名 Aldenon、Aldenonc、IY-NT-R + [7] |
作用方式 抑制剂 |
作用机制 质子泵抑制剂 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2007-12-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H18N4O2S |
InChIKeyHRRXCXABAPSOCP-UHFFFAOYSA-N |
CAS号172152-36-2 |
关联
105
项与 艾普拉唑 相关的临床试验CTR20253118
艾普拉唑肠溶片（5mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列交叉生物等效性试验
CTR20252856
评估受试制剂艾普拉唑肠溶片（规格：5 mg）与参比制剂壹丽安（规格：5 mg）在健康成年参与者空腹和餐后状态下的单中心、开放、随机、单剂量、两序列、交叉生物等效性试验
CTR20252529
艾普拉唑肠溶片在健康受试者中单次口服给药、随机、开放、四周期、完全重复生物等效性试验
100 项与 艾普拉唑 相关的临床结果
登录后查看更多信息
100 项与 艾普拉唑 相关的转化医学
登录后查看更多信息
100 项与 艾普拉唑 相关的专利（医药）
登录后查看更多信息
147
项与 艾普拉唑 相关的文献（医药）2025-11-04Microbiology Spectrum
Article
作者: Hu, Xinxin ; Sun, Wei ; Li, Congran ; Zhang, Zhimeng ; Yang, Xinyi ; You, XueFu ; Lu, Xi ; Sun, Lang ; Pang, Jing ; Nie, Tongying ; Yang, Lu
ABSTRACT:
Ilaprazole, a proton pump inhibitor, has been approved and marketed in Korea
and China for the treatment of gastric ulcer, duodenal ulcer,
gastroesophageal reflux disease, and erosive esophagitis. This study
evaluated the
in vitro
antibacterial activity of ilaprazole
against
Helicobacter pylori
(
H. pylori
),
both as a single agent and in combination with other components used in the
standard quadruple therapy. The antibacterial activity of ilaprazole was
tested on 25
H
.
pylori
strains, including
the clinical isolates resistant to clarithromycin (CLA), amoxicillin (AMX),
levofloxacin, and/or metronidazole. Antibacterial activities and killing
kinetics were evaluated by the minimal inhibitory concentration (MIC) and
time-kill curve determination, respectively. Synergistic effects were
assessed in checkerboard and time-kill assays. Resistance development was
assessed through serial passage over 12 cycles. Ilaprazole exhibited potent
in vitro
antibacterial activity against
H.
pylori
, with MIC
50
and MIC
90
values of 8
µg/mL, demonstrating activity against drug-resistant strains. When
combined with CLA, ilaprazole showed synergistic effects against 36% of the
tested strains. Notably, the quadruple combination of ilaprazole + AMX + CLA
+ bismuth potassium citrate exhibited an obvious synergistic effect.
Importantly, repeated exposure to ilaprazole over 12 passages did not induce
resistance. These findings highlight the promising
in vitro
antibacterial activity of ilaprazole against
H. pylori
,
including drug-resistant strains, and its potential to enhance the efficacy
of quadruple therapy. The study supports the inclusion of ilaprazole in
treatment regimens for
H. pylori
infections, offering a
compelling rationale for its clinical use.
IMPORTANCE:
H. pylori
infection remains a major global health issue,
contributing to a wide range of gastric diseases. Despite current
treatment regimens, rising antibiotic resistance limits their
effectiveness, emphasizing the need for novel therapeutic approaches.
This study highlights the promising
in vitro
antibacterial activity of ilaprazole against
H. pylori
,
including drug-resistant strains. Ilaprazole not only exhibits direct
antimicrobial effects but also enhances the efficacy of combination
therapy, particularly in quadruple therapy regimens, which are
recommended as first-line treatment. The findings demonstrate that
ilaprazole, in combination with clarithromycin, shows synergistic
effects, offering a potential solution to overcome antibiotic resistance
challenges. Importantly, repeated exposure to ilaprazole did not induce
resistance, a critical factor for its long-term use. These results
provide compelling evidence for ilaprazole’s inclusion in
clinical treatment strategies, contributing to improved eradication
rates and better patient outcomes in
H. pylori
management.
2025-11-01HELICOBACTER
Different Doses of Ilaprazole for Dual Therapy Versus Bismuth‐Quadruple Therapy for
Helicobacter pylori
Infection: A Three‐Arm, Randomized Clinical Trial
Article
作者: Zhu, Yuanmin ; Liu, Xiuqing ; Wang, Yali ; Du, Shiyu ; Zu, Ming ; Guo, Hongwei ; Ding, Shigang ; Guo, Yinyan ; Han, Qiang ; Cheng, Yanli
ABSTRACT:
Background:
Current
Helicobacter pylori
(
H. pylori
)
eradication regimens—standard triple, bismuth‐containing quadruple, and non‐bismuth quadruple therapies—still face issues such as adverse effects and poor compliance. High‐dose dual therapy, with its simplicity, lower pill burden, and comparable efficacy, has recently gained attention. However, existing studies are largely single‐center with small sample sizes and lack sufficient evidence‐based support. This study aims to further evaluate the efficacy and safety of ilaprazole‐based dual and quadruple therapies for
H. pylori
eradication.
Methods:
This was a prospective, multicenter, randomized controlled, non‐inferiority clinical trial conducted at five hospitals from January to November 2023. A total of 480 patients were randomly assigned to one of three treatment groups for 14 days: Group A (ilaprazole 5 mg, amoxicillin 1 g, clarithromycin 500 mg, and bismuth potassium citrate 220 mg, all administered twice daily), Group B (ilaprazole 5 mg twice daily and amoxicillin 1 g three times daily), and Group C (ilaprazole 10 mg twice daily and amoxicillin 1 g three times daily). The eradication rates, adverse events, and patient compliance were recorded.
Results:
The eradication rates of
H. pylori
in Groups A, B, and C were 76.9%, 88.1%, and 88.7% (
p
= 0.004) by intention‐to‐treat analysis, respectively, and 78.3%, 90.4%, and 91.0% (
p
= 0.001) using modified intention‐to‐treat analysis, and 81.8%, 92.1%, 92.2% (
p
= 0.005) by per‐protocol analysis. The adverse event rates were 28.0%, 10.2%, 10.8% in Groups A, B, and C, respectively (
p <
0.001), while patient compliance rates were 91.1%, 98.1%, 98.7%, respectively (
p =
0.001). Sex, smoking history, alcohol intake, and sharing tableware or cups did not affect the efficacy of the three treatment regimens.
Conclusions:
The standard‐ or high‐dose dual therapy with ilaprazole demonstrated superior efficacy, safety, and patient compliance compared to quadruple therapy. No significant differences were observed between these dual therapies, which are expected to become promising alternatives for the primary treatment of
H. pylori
infection.
Trial Registration:
Chinese Clinical Trial Registry: ChiCTR2400086862
2025-03-14SCIENCE
Excited-state configuration of nitroarenes enables oxidative cleavage of aromatics over alkenes
Article
作者: Leonori, Daniele ; Hitoshio, Kenshiro ; Ruffoni, Alessandro ; Marchand, Isabelle ; Olivier, Wesley J. ; Arpa, Enrique M. ; Poisson, Thomas ; Błyszczyk, Piotr ; Gomez-Mendoza, Miguel ; de la Peña O’Shea, Víctor
The ozonolytic deconstruction of aromatics remains a challenge in organic chemistry. Ozone preferentially reacts with alkenes over arenes, meaning that once the initial aromatic cleavage occurs, the dearomatized products are inherently more reactive than the starting materials. Consequently, the process cannot be halted, resulting in full oxidation. Addressing this challenge requires subverting intrinsic rules of chemoselectivity to transform a less reactive substrate in the presence of a more reactive one. We demonstrate that this concept can be achieved by using photoexcited nitroarenes. Crucial to the success of this chemoselective process is the use of a nitroarene that is preferentially excitable to a triplet π,π* state over the n,π* state. This switch in excited-state configuration provides an otherwise inaccessible manifold, in which oxidative cleavage is diverted toward aromatics in the presence of alkenes.
100 项与 艾普拉唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 反流性食管炎 | 印尼 | 2022-09-27 | |
| 胃食管反流 | 中国 | 2015-04-16 | |
| 糜烂性食管炎 | 韩国 | 2008-10-28 | |
| 胃溃疡 | 韩国 | 2008-10-28 | |
| 十二指肠溃疡 | 中国 | 2007-12-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性胃食管反流病 | 临床3期 | 美国 | 2018-10-31 | |
| 非糜烂性反流病 | 临床3期 | 美国 | 2018-10-31 | |
| 幽门螺杆菌引起的十二指肠溃疡 | 临床3期 | 美国 | 2012-12-01 | |
| 消化性溃疡 | 临床3期 | 美国 | 2012-12-01 | |
| 消化性溃疡出血 | 临床2期 | - | 2014-02-01 | |
| 幽门螺杆菌感染 | 临床申请批准 | 中国 | 2022-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 176 | 網網廠築鹹製廠鑰憲衊(鬱餘鹽觸繭憲繭選艱窪) = 網淵膚廠遞簾蓋構糧顧 鏇憲構構夢壓憲鹹願膚 (遞製顧顧顧憲範壓獵簾 ) 更多 | 积极 | 2019-05-01 | |||
rabeprazole | 網網廠築鹹製廠鑰憲衊(鬱餘鹽觸繭憲繭選艱窪) = 積繭構齋遞醖獵廠糧夢 鏇憲構構夢壓憲鹹願膚 (遞製顧顧顧憲範壓獵簾 ) 更多 | ||||||
临床3期 | 537 | 蓋簾鑰齋積醖艱獵獵顧(構膚範觸築齋簾憲餘膚) = 廠鏇鏇遞網網糧願壓繭 衊鬱鹹膚築衊顧襯網鹽 (鑰夢齋齋鹹艱廠蓋觸製 ) 更多 | 相似 | 2018-05-01 | |||
蓋簾鑰齋積醖艱獵獵顧(構膚範觸築齋簾憲餘膚) = 範獵顧顧獵鏇壓艱襯糧 衊鬱鹹膚築衊顧襯網鹽 (鑰夢齋齋鹹艱廠蓋觸製 ) 更多 | |||||||
临床2期 | - | 範範淵蓋願觸憲顧築鹹(遞獵範壓願餘構獵夢蓋) = 糧觸構築壓鹹壓鹽憲醖 糧齋鹽餘網鏇醖糧鬱餘 (淵鏇壓獵簾網鹹鏇獵範, (86.73%)) 更多 | - | 2016-12-01 | |||
範範淵蓋願觸憲顧築鹹(遞獵範壓願餘構獵夢蓋) = 蓋選窪選蓋鹽觸餘網鏇 糧齋鹽餘網鏇醖糧鬱餘 (淵鏇壓獵簾網鹹鏇獵範, (81.40%)) 更多 | |||||||
临床3期 | 494 | Ilaprazole 10mg/d | 廠築獵淵窪鹹獵願範鏇(襯繭願鑰構壓簾蓋獵範) = 鑰簾廠簾艱鹽廠夢糧繭 壓淵齋衊繭淵鹽築選鑰 (蓋夢憲憲襯夢築壓壓廠 ) | 积极 | 2012-01-01 | ||
Omeprazole 20mg/d | 廠築獵淵窪鹹獵願範鏇(襯繭願鑰構壓簾蓋獵範) = 膚鑰製顧顧憲顧顧獵膚 壓淵齋衊繭淵鹽築選鑰 (蓋夢憲憲襯夢築壓壓廠 ) | ||||||
临床2期 | 235 | Ilaprazole 5 mg | 構窪艱遞觸選繭醖簾廠(淵餘鬱憲築壓範選夢餘) = 獵觸淵鬱鑰顧鑰簾淵淵 膚築鹹鹹鑰齋顧淵膚襯 (蓋廠鬱範觸網壓鹽壓蓋 ) | - | 2011-04-01 | ||
Ilaprazole 10 mg | 構窪艱遞觸選繭醖簾廠(淵餘鬱憲築壓範選夢餘) = 窪鏇鏇膚遞製製蓋鹽製 膚築鹹鹹鑰齋顧淵膚襯 (蓋廠鬱範觸網壓鹽壓蓋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用